Caplin Point Laboratories Ltd (CAPLIPOINT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 640544, "name": "Caplin Point Lab", "stock_name": "Caplin Point Lab", "full_name": "Caplin Point Laboratories Ltd", "name_url": "stocks-analysis/caplin-point-lab", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,661.90", "chg": -26.7, "chgp": "-1.58%", "dir": -1, "prev_price": "1,688.60", "mcapval": "12,733.00 Cr", "mcap": "Small Cap", "scripcode": 524742, "symbol": "CAPLIPOINT", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE475E01026", "curr_date": "Mar 13", "curr_time": "", "bse_nse_vol": "72.27 k", "exc_status": "Active", "traded_date": "Mar 13, 2026", "traded_date_str": "2026 03 13", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/caplin-point-lab-640544-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Caplin Point Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3875590", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CaplinPointLabo_mojoScore_3875590.png", "date": "2026-03-06 10:10:44", "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Why is Caplin Point Laboratories Ltd falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-caplin-point-laboratories-ltd-fallingrising-3875038", "imagepath": "", "date": "2026-03-06 01:18:10", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Caplin Point Laboratories has been on a downward trajectory over the past week, falling 6.04%, which notably exceeds the Sensex’s decline of 2.71% during the same period. The trend extends over the last month, where the stock has shed 14.71%, significantly underperforming the Sensex’s 3.96% drop. Year-to-date, the stock is down 11.91%, nearly double the Sensex’s 6.11% decline. Over the last year, the stock has generated a negative return of 12.06%, contrasting sharply with the Sensex’s positive 8.53% gain. Despite this, the company’s longer-term performance remains robust, with a three-year return of 144.37% and a five-year return of 253.24%, both substantially outperforming the benchmark.</p>\n<p><strong>Technical Indicators and Tra..." }, { "title": "Caplin Point Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3850562", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3850562.png", "date": "2026-02-23 10:10:51", "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Caplin Point Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3850542", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3850542.png", "date": "2026-02-22 10:10:29", "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Caplin Point Laboratories Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3832619", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3832619.png", "date": "2026-02-11 10:11:06", "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook." }, { "title": "Caplin Point Laboratories Ltd Faces Bearish Technical Shift Amid Market Volatility", "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-faces-bearish-technical-shift-amid-market-volatility-3827827", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_technicaldot_3827827.png", "date": "2026-02-09 08:01:24", "description": "Caplin Point Laboratories Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. The stock’s recent decline of 4.29% to ₹1,820.00, coupled with deteriorating moving averages and bearish MACD readings, suggests mounting pressure on the pharmaceutical firm’s near-term outlook." }, { "title": "Caplin Point Laboratories Gains 2.70%: Mixed Signals Amid Record Quarterly Results", "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-gains-270-mixed-signals-amid-record-quarterly-results-3826471", "imagepath": "", "date": "2026-02-07 16:07:14", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens week at Rs.1,799.60, rising 1.23% despite Sensex decline</p>\n <p><strong>4 Feb:</strong> Technical momentum shift noted amid mixed market signals</p>\n <p><strong>5 Feb:</strong> Q3 FY26 results reveal strong profit growth but valuation concerns</p>\n <p><strong>6 Feb:</strong> Mixed quarterly performance reported amid margin pressure, stock dips 3.99%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,777.75</div></div>\n <div class=\"stat-item\"><div class..." }, { "title": "Caplin Point Laboratories Ltd Reports Mixed Quarterly Performance Amid Margin Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-reports-mixed-quarterly-performance-amid-margin-pressure-3824597", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_fintrenddot_3824597.png", "date": "2026-02-06 16:00:18", "description": "Caplin Point Laboratories Ltd has reported its December 2025 quarter results, marking record highs in net sales and profitability metrics, yet facing challenges in operational efficiency and return ratios. The company’s financial trend has shifted from positive to flat, reflecting a nuanced performance that investors must carefully analyse amid a volatile pharmaceutical sector backdrop." }, { "title": "Are Caplin Point Laboratories Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-caplin-point-laboratories-ltd-latest-results-good-or-bad-3822915", "imagepath": "", "date": "2026-02-05 19:27:34", "description": "Caplin Point Laboratories Ltd reported its Q2 FY26 results, showcasing a consistent operational performance with notable metrics. The company achieved net sales of ₹534.04 crores, reflecting a year-on-year growth of 10.54%. This marks a continuation of double-digit revenue growth for seven consecutive quarters, indicating robust demand in its key markets, particularly in Latin America and Africa.\n\nThe net profit for the quarter stood at ₹154.45 crores, which represents an 18.08% increase compared to the previous year. This growth in profitability was supported by an operating margin of 35.42%, up 132 basis points from the same quarter last year, demonstrating effective cost management and operational efficiency.\n\nHowever, the company faced challenges in terms of market performance, as its stock has underperformed the broader market indices over the past year, leading to questions regarding the adequacy of c..." } ], "total": 588, "sid": "640544", "stock_news_url": "https://www.marketsmojo.com/news/caplin-point-laboratories-640544" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "13-Mar-2026", "details": "Press release regarding receipt of final approval by our subsidiary Caplin Steriles Limited from USFDA for the Potassium Phosphates Injection USP", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Cessation", "datetime": "03-Mar-2026", "details": "Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3 2026.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "28-Feb-2026", "details": "Press Release regarding receipt of final approval by our Subsidiary Caplin Steriles Limited from USFDA for the Desmopressin Acetate Injection USP", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Caplin Point Laboratories Ltd has declared <strong>150%</strong> dividend, ex-date: 12 Sep 25", "dt": "2025-09-12", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Caplin Point Laboratories Ltd has announced <strong>2:10</strong> stock split, ex-date: 19 Oct 16", "dt": "2016-10-19", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock opens week at Rs.1,799.60, rising 1.23% despite Sensex decline

4 Feb: Technical momentum shift noted amid mixed market signals

5 Feb: Q3 FY26 results reveal strong profit growth but valuation concerns

6 Feb: Mixed quarterly performance reported amid margin pressure, stock dips 3.99%

Week Open

Rs.1,777.75

Read full news article

Caplin Point Laboratories Ltd Reports Mixed Quarterly Performance Amid Margin Pressure

2026-02-06 16:00:18

Caplin Point Laboratories Ltd has reported its December 2025 quarter results, marking record highs in net sales and profitability metrics, yet facing challenges in operational efficiency and return ratios. The company’s financial trend has shifted from positive to flat, reflecting a nuanced performance that investors must carefully analyse amid a volatile pharmaceutical sector backdrop.

Read full news article

Are Caplin Point Laboratories Ltd latest results good or bad?

2026-02-05 19:27:34

Caplin Point Laboratories Ltd reported its Q2 FY26 results, showcasing a consistent operational performance with notable metrics. The company achieved net sales of ₹534.04 crores, reflecting a year-on-year growth of 10.54%. This marks a continuation of double-digit revenue growth for seven consecutive quarters, indicating robust demand in its key markets, particularly in Latin America and Africa. The net profit for the quarter stood at ₹154.45 crores, which represents an 18.08% increase compared to the previous year. This growth in profitability was supported by an operating margin of 35.42%, up 132 basis points from the same quarter last year, demonstrating effective cost management and operational efficiency. However, the company faced challenges in terms of market performance, as its stock has underperformed the broader market indices over the past year, leading to questions regarding the adequacy of c...

Read full news article